Merck & Co., Inc. Increase (Decrease) in Accounts Receivable
Merck & Co., Inc. (MRK) reported Increase (Decrease) in Accounts Receivable of $1.09 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-02-24
- Merck & Co., Inc. increase (decrease) in accounts receivable for the quarter ending 2009-12-31 was $14.00M, a 98.63% decline year-over-year.
- Merck & Co., Inc. increase (decrease) in accounts receivable for the quarter ending 2009-09-30 was $124.00M, a 54.91% decline year-over-year.
- Merck & Co., Inc. increase (decrease) in accounts receivable for the quarter ending 2008-12-31 was $1.02B.
- Merck & Co., Inc. increase (decrease) in accounts receivable for the quarter ending 2008-09-30 was $275.00M.
- Merck & Co., Inc. increase (decrease) in accounts receivable for fiscal 2025 was $1.09B, a 346.72% increase from fiscal 2024.
- Merck & Co., Inc. increase (decrease) in accounts receivable for fiscal 2024 was $244.00M, a 78.75% decline from fiscal 2023.
- Merck & Co., Inc. increase (decrease) in accounts receivable for fiscal 2023 was $1.15B, a 78.26% increase from fiscal 2022.
- Merck & Co., Inc. increase (decrease) in accounts receivable for fiscal 2022 was $644.00M, a 68.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.09B 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $244.00M 10-K · filed 2026-02-24 | ||||
| 2023-12-31 | $1.15B 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | $644.00M 10-K · filed 2025-02-25 | ||||
| 2021-12-31 | $2.03B 10-K · filed 2024-02-26 | ||||
| 2020-12-31 | $1.00B 10-K · filed 2023-02-24 | ||||
| 2019-12-31 | -$92.00M 10-K · filed 2022-02-25 | -$294.00M 10-K · filed 2020-02-26 | |||
| 2018-12-31 | $418.00M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | -$297.00M 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $619.00M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | $480.00M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $554.00M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | -$436.00M 10-K · filed 2016-02-26 | ||||
| 2012-12-31 | -$349.00M 10-K · filed 2015-02-27 | ||||
| 2011-12-31 | $1.17B 10-K · filed 2014-02-27 | ||||
| 2010-12-31 | $1.09B 10-K · filed 2013-02-28 | ||||
| 2009-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $138.00M derived: sum of 2 quarters · filed 2012-02-28 | -$165.00M 10-K · filed 2012-02-28 | $165.20M 10-K · filed 2010-03-01 | |
| 2009-09-30 | $124.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-29 | -$179.00M 10-Q · filed 2009-10-29 | |||
| 2009-06-30 | -$303.00M 10-Q · filed 2009-07-24 | ||||
| 2008-12-31 | $1.02B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $1.30B derived: sum of 2 quarters · filed 2011-02-28 | $889.00M 10-K · filed 2011-02-28 | -$889.40M 10-K · filed 2010-03-01 | |
| 2008-09-30 | $275.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-29 | -$132.00M 10-Q · filed 2009-10-29 | |||
| 2008-06-30 | -$407.00M 10-Q · filed 2009-07-24 | ||||
| 2007-12-31 | -$290.70M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |